We have investigated the possible role of anti-tumor antibody detected in a case of follicular lymphoma which demonstrated the spontaneous reduction of leukemic tumor cells. The tumor cells genotypically had monoclonal rearrangements of the immunoglobulin J H and C genes, but phenotypically exhibited surface IgG, A, and ( dual positivity). The culture study revealed that IgG, at least, was derived from the serum, and IgA was expressed intrinsically. Furthermore, the positive correlation between the densities of both surface light chains on two-color flow cytometry, the rosette formation study and its inhibition test by the Fc␥ fragment suggested that the serum IgG combined with some antigens on the tumor-cell surface via its Fab portion and with the Fc␥ receptor of macrophages via its Fc portion. From these findings, we regarded the present case as an anti-tumor antibody-coated lymphoma. In addition, the phagocytic study disclosed that the serum-derived IgG, at least, might have induced the phagocytosis of circulating lymphoma cells by macrophages. In conclusion, the existence of the anti-tumor antibody-coated lymphoma may be helpful in clarifying the immunological mechanism of the spontaneous regression occasionally seen in lymphomas.
Introduction
Spontaneous tumor regression is uncommonly seen in certain cancers including lymphomas, but its mechanism remains unknown although the immune system seems to play a role in such phenomenon.
We have hitherto assessed the clonality of conventionally diagnosed B cell lymphomas by single-color flow cytometric (FCM) analysis of surface immunoglobulin and light chains referred to as -analysis 1 or -imaging, 2, 3 which is a simple, but useful method for verifying B cell clonality.
In this way, we have investigated 97 cases of B cell lymphoma expressing surface immunoglobulin and discovered that five (5%; 5/97) of them unusually expressed both and light chains, which was also confirmed by two-color FCM analysis. Thus, provisionally, we called these cases -dualpositive lymphoma. Incidentally, the pathological diagnoses of these five cases were as follows: two follicular lymphomas, two mantle cell lymphomas and one diffuse large cell lymphoma. All cases genotypically showed the rearrangement of only one light-chain gene. One follicular lymphoma and the two mantle cell lymphomas were treated with chemotherapy from the beginning, while the diffuse large cell lymphoma and the other follicular lymphoma were followed-up untreated for several reasons. Although the treated cases did not suggest any immunological implications of a -dual-positive nature, Correspondence: M Nakano, Medicine & Health Sciences Institute, Tokyo Medical University, 6-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo 160-0023, Japan; Fax: 001-81-3-5323-0321 Received 17 May 1999; accepted 22 September 1999 the untreated cases of diffuse large cell lymphoma, which have already been reported, 4 and follicular lymphoma, pursued interesting clinical courses.
The diffuse large cell lymphoma remained localized for a long time and showed clinically indolent behavior despite being an aggressive lymphoma. The patient has still received no treatment, except biopsical resection, and has shown no evidence of relapse for 49 months since diagnosis. Ultimately, taking several immunological findings into account, it was speculated that anti-tumor antibody against some cell-surface molecules including idiotype might have controlled the growth of the lymphoma. However, a further study seemed to be needed in order to clarify accurately the immunological significance of the -dual-positive lymphoma.
Fortunately, the other untreated case could be investigated in more detail. The patient was diagnosed as having a follicular and small cleaved cell lymphoma in the leukemic phase, 5 for which a 'watch and wait' approach could be allowed for follow-up, 6 and showed a spontaneous reduction of the leukemic tumor cells during the untreated 'watch and wait' period of about 9 months. In addition, we were able to repeatedly sample and analyze precisely the tumor cells and serum.
In this report, we show the clinical findings and outcomes of immunological studies on the present -dual-positive lymphoma case, and discuss the relationship between the spontaneous reduction of leukemic lymphoma cells and its immunological mechanism.
Materials and methods

Case report
A 40-year-old woman visited a local clinic because of stomach pain in June 1995, and a blood examination revealed marked lymphocytosis. Thereafter, the patient came to our hospital in July 1995. At that time, no surface lymph nodes were palpable on physical examination, but computed tomography showed infradiaphragmatic non-bulky lymphadenopathies (para-aortic and mesenteric areas). The white blood cell count was 50 400/l, and almost all the cells were medium-sized lymphoid cells including a few cleft cells. There was neither anemia nor thrombocytopenia, although bone marrow infiltration was revealed by biopsy. These lymphoid cells were phenotypically CD10
− . In addition, a chromosomal abnormality of t(14;18)(q32;q21) was detected.
From these findings, we diagnosed the patient as being in the leukemic phase of follicular lymphoma, based on the FAB classification of chronic lymphoid leukemias. 5 Because the performance status was level 0 (ECOG scale 7 ) and the patient showed no lymphoma-related complaints, although the stage was assessed as IV according to the Ann Arbor system, 8 we followed-up the patient for the first 9 months, adopting a 'watch and wait' policy. During this period, the leukemic cells were reduced spontaneously to 15 100/l, as shown in Figure  1 , and the bone marrow lesion also improved naturally. However, in April 1996, we started treating the patient with the CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) protocol because the infradiaphragmatic lymph nodes remained unchanged in size.
The patient had delivered a child, but had no history of blood transfusion. Moreover, she had no autoimmune disease, and no immunological abnormalities such as rheumatoid factor or monoclonal gammopathy were detected in her serum.
Cell preparation
The mononuclear cells were isolated from the patient's heparinized peripheral blood on Ficoll-Hypaque sedimentation gradients and subdivided into two samples. One was prepared as a sample of fresh cells. The other was cultured in RPMI1640 with 10% fetal calf serum (FCS) for 1 week at 37°C and used as a sample of cultured cells.
Analysis of immunoglobulin and bcl-2 genes
High molecular weight DNAs extracted from the prepared fresh cells by standard procedures were digested with restriction enzymes (EcoRI, HindIII, BamHI, SacI, BamHI plus HindIII, and EcoRI plus HindIII) and fractionated by 0.9% agarose gel electrophoresis. DNA fragments were transferred on to nylon membrane filters by Southern blotting. 9 The filters were hybridized to nick-translated 32 P-radiolabeled DNA probes specific for the immunoglobulin heavy-chain gene (JH) (Oncor, Gaithersburg, MD, USA), the light-chain gene (J) (Oncor) and the light-chain gene (C) (pHuCK; American Type Culture Collection, Rockville, MD, USA), and for the bcl-2 gene (Oncogene Science, Manhasset, NY, USA).
Figure 1
Clinical course without treatment. The white blood cell count fell spontaneously from 50 400 to 15 100/l over 9 months, while infradiaphragmatic non-bulky lymphadenopathies (para-aortic and mesenteric nodes) remained unchanged in size throughout the same period.
Leukemia
FCM analysis of surface immunoglobulin and Fc␥R
The fresh cells were incubated in RPMI1640 for 60 min at 4°C to separate non-specifically adsorbed serum immunoglobulin and were suspended in Dulbecco's phosphate buffer saline (D-PBS; ICN Biomedicals, Aurora, OH, USA) at 1.0 × 10 6 cells/ml. Some of the cultured cells were suspended in D-PBS at 1.0 × 10 6 cells/ml and the other cells were further incubated at 1.0 × 10 6 cells/ml in RPMI 1640 with 10% of the patient's serum plus 0.1% sodium azide (NaN 3 ) to inhibit the internalization of immunoglobulin for 60 min at 4°C, and finally resuspended in D-PBS at 1.0 × 10 6 cells/ml. These prepared cells were analyzed by FCM.
The FCM analysis was carried out with a fluorescence-activated cell scanner (FACScan; Becton Dickinson Electronics, Mountain View, CA, USA). The antibodies used in this study were as follows: fluorescein isothiocyanate (FITC)-conjugated F(abЈ) 2 fragments of goat polyclonal antibodies specific for human immunoglobulin , light chains and , ␦, ␣, ␥ heavy chains (Tago, Burlingame, CA, USA); phycoerythrin (PE)-conjugated F (abЈ) 2 
Rosette-forming study
The cultured cells were subdivided into non-adherent cells and adherent cells on the tissue culture dish. The non-adherent cells were used at 1.0 × 10 6 cells/ml after pretreatment with 10% FCS () or 10% of the patient's serum () for 20 min at 37°C, whereas 5.0 × 10 5 cells/ml of the adherent cells were either used untreated () or treated with chromatography-purified human IgG-Fc (Fc␥) fragment (Cappel Products, Aurora, OH, USA) () for 20 min at 37°C. The Fc␥ fragment was used to block Fc␥ receptor at 50 g/1 × 10 6 cells and washed twice with RPMI 1640 plus 10% FCS at 37°C. The cell combinations for rosette formation were as follows: cells + cells, cells + cells, and cells + cells. The rosette-forming study was carried out in phenol-free Iscove's modified Dulbecco's medium (Gibco BRL, Life Technologies, Rockville, MD, USA) for 60 min at 4°C. After non-rosette-forming cells had been removed by gentle washing, the rosette-forming cells were morphologically assessed using an inverted microscope and they were also identified with both FITC-labeled anti-light chain and PE-labeled anti-CD14 murine monoclonal antibodies (LeuM3; Becton Dickinson), and a laser scanning confocal microscope system (InSIGHT plus; Meridian Instruments, Okemos, MI, USA).
Isolation of tumor cells by positive selection
The tumor cells were separated from the non-adherent cells by 'positive selection'. Procedures for positive selection were as follows: the non-adherent cells were incubated at 1.0 × 10 6 cells/ml with 5 g/1 × 10 6 cells of anti-human light chain mouse antibody (PharMingen) for 60 min at 4°C with gentle shaking. The pretreated cells were collected by centrifugation at 800 g for 10 min and the supernatant was discarded. The cells were resuspended and washed twice with Hank's balanced salt solution (pH 7.4) to remove all unbound antibodies. These cells were used as the cells sensitized with antihuman light chain mouse antibody. Next, Dynabeads M-450 goat anti-mouse IgG (Dynal, Lake Success, NY, USA) was added to the sensitized cells, to a final concentration of at least 2 × 10 7 Dynabeads/ml (cell/beads ratio = 1:20) and the cells were incubated for 10 min under bidirectional rotation. The Dynabeads with cells attached were collected with a magnetic particle concentrator (Dynal), and then the supernatant was pipetted off. After being washed in PBS (pH 7.4) with 0.1% bovine serum albumin twice, the cells were cultured in RPMI 1640 with 10% FCS at 37°C overnight to detach the Dynabeads M-450 goat anti-mouse IgG. These detached cells were cultured in RPMI1640 with 10% FCS for 3 more days at 37°C and applied as tumor cells for phagocytic study.
Phagocytic study
Four days before the phagocytic study, in order to obtain lively monocytes/macrophages, mononuclear cells were isolated again from heparinized peripheral blood of the patient and separated into non-adherent cells and adherent cells on the tissue culture dish. The adherent cells were prepared as monocytes/macrophages.
As previously reported, 10 before the study, the monocytes/macrophages at 5.0 × 10 5 cells/ml were activated by 100 U/ml of human recombinant interferon ␥ (rhIFN ␥; Genzyme Corporation, Boston, Malvern, MA, USA) and 100 ng/ml of macrophage colony-stimulating factor (M-CSF; Genzyme Corporation) at 37°C overnight, and the tumor cells at 1.0 × 10 6 cells/ml were stained by 4 M of PKH-26 dye (Zynaxix Cell Science, Malvern, PA, USA) at room temperature for 3 min. Secondly, both cells were co-incubated with 10% of the patient's serum and monitored under a confocal microscope for 3 and 6 h.
Characterization of anti-tumor antibody
To characterize the present anti-tumor antibody, the IgG was purified from the patient's serum with ImmunoPure IgG Purification Kit containing ImmunoPure IgG Purification Buffers, Protein A AffinityPak Columns and Excellulose Prepacked GF-5 Desalting Columns (Pierce; Rockford, IL, USA) and then the F (abЈ) 2 fragment was purified from the purified IgG with ImmunoPure F (abЈ) 2 Preparation Kit containing ImmunoPure IgG Binding Buffer, ImmunoPure IgG Elution Buffer, Protein A Affinity-Pak Columns, Immobilized Pepsin and Accessory Kit (Pierce). Lastly, 1 g of the F (abЈ) 2 fragments was added to the above mentioned 1 week-cultured cells at 1.0 × 10 6 cells/ml in RPMI 1640 with 0.1% NaN 3 . After incubation for 60 min at 4°C, the cells were double-stained with both FITClabeled anti-and PE-labeled anti-light chain antibodies and analyzed by two-color FCM.
Secondly, 1.0 × 10 6 sample cells/ml were activated with T cell mitogen (phytohemagglutinin; PHA) for 2 weeks at 37°C and then double-stained with FITC-labeled anti-CD3 murine monoclonal antibody (Leu4; Becton Dickinson) and PE-labeled anti-human HLA-A, B, C murine monoclonal antibody (PharMingen) or anti-HLA-DR murine monoclonal antibodies (Becton Dickinson) for 30 min at 4°C and then washed three times with D-PBS. Afterwards, the cells were analyzed by twocolor FCM. On the other hand, the PHA-activated cells were incubated at 1.0 × 10 6 cells/ml in RPMI 1640 with 10% of the patient's serum for 60 min at 4°C and then stained with FITClabeled anti-CD3 and PE-labeled anti-␥ heavy chain or antilight chain antibodies. After washing with D-PBS three times, the cells were analyzed by two-color FCM.
Furthermore, mononuclear cells obtained from the peripheral blood of three healthy volunteers, whose normal B cells were confirmed to include surface IgA expressing cells by using FITC-labeled anti-␣ heavy chain antibody and singlecolor FCM, were incubated at 1.0 × 10 6 cells/ml with 10% of the patient's serum for 60 min at 4°C and then double-stained with FITC-labeled anti-light chain antibody and PE-labeled anti-light chain antibody. After washing, the cells were analyzed by two-color FCM.
Results
Immunogenotype and bcl-2 gene of tumor cells
In genotyping, the fresh sample cells showed one (EcoRI and BamHI plus HindIII) or two rearranged bands (HindIII) of the JH gene and a single rearrangement (BamHI) of the C gene, whereas the J gene remained in the germline configuration (Figure 2a, b, c) . In addition, the bcl-2 probe detected the rearrangement of the major breakpoint region of the bcl-2 gene from the sample DNAs digested with EcoRI and EcoRI plus HindIII (Figure 2d ).
Immunophenotype of fresh tumor cells
The single-color FCM analysis revealed that the fresh cells expressed both and light chains on their surface. Furthermore, by using the two-color technique, the cells were found to show dual positivity and a positive correlation between the fluorescence intensities of both light chains (Figure 3a,  top) . In addition, ␣ and ␥ heavy chains were detected on the cell surface, the former being bright-positive, whereas the latter showed dull-positive fluorescence intensity (Figure 3a , middle). The cells were CD16 − , CD32
+ and CD64 − , but there seemed to be no correlation between the fluorescence intensities of ␥ heavy chain and CD32 (Figure 3a, bottom) .
Immunophenotype of cultured tumor cells
The untreated cultured cells lost their surface ␥ heavy chain and light chain (IgG), while the ␣ heavy chain and light chain (IgA) were retained (Figure 3b, top and middle) . However, after incubation with the patient's serum, the cells were recoated with ␥ heavy chain and regained their dual positivity (Figure 3c , top and middle) which was observed even after the cells were pretreated with an excess amount (50 g/10 6 cells) of the Fc␥ fragment to block Fc␥R (data not shown). In addition, the cultured cells showed no dual 
Figure 3
Immunoglobulin phenotype and CD32 (Fc␥R II) expression of fresh and cultured cells. The fresh cells showed dual positivity on two-color FCM (a, upper panel). The ␣ and ␥ heavy chains were detected on the cells, but the former showed bright-positive and the latter dull-positive fluorescence intensities (a, middle panel). Moreover, these cells expressed CD32 (a, lower panel). On the other hand, the cells cultured for 1 week at 37°C lost their surface light chain and ␥ heavy chain (b, upper and middle panels), whereas surface light chain, ␣ heavy chain and CD32 were retained (b, middle and lower panels). However, after incubation with the patient's serum, these cultured cells became coated with ␥ heavy chain again (c, middle panel), and regained their dual positivity (c, upper panel), while CD32 remained positive (c, lower panel). In addition, a positive correlation was observed between the fluorescence intensities of both and light chains on the cell surface (the upper panels of a and c), whereas there seemed to be no correlation between ␥ heavy chain and CD32 (the lower panels of a and c).
positivity even after treatment with aggregated human IgG (Polyglobin; Bayer, Pittsburgh, PA, USA) (data not shown).
On the other hand, as shown at the top of Figure 3c , the patient's serum-treated cultured cells also presented a positive correlation between the fluorescence intensities of two light chains, while those cells were CD32 + , but CD16 − , and there was no correlation between the fluorescence intensities of CD32 and ␥ heavy chain, as was with the fresh cells ( Figure  3b, c, bottom) .
Serum-mediated binding of tumor cells and monocytes/macrophages
The rosette-forming study revealed that the non-adherent cells pretreated with FCS only ( cells) did not combine with the non-pretreated adherent cells ( cells). However, the nonadherent cells pretreated with the patient's serum ( cells) and the cells formed rosettes (Figure 4a ; inverted microscope). Incidentally, it was confirmed by using a laser scanning confocal microscope that the rosette-forming small round-shaped cells and large irregular-shaped cells were FITC green-stained light chain-positive (tumor cells) and PE red-stained CD14-positive (monocytes/macrophages) respectively (Figure 4b ).
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Figure 4
Rosette-forming and phagocytic studies. The patient's serum-pretreated non-adherent cells (small, round cells) formed rosettes with non-pretreated adherent cells (large, irregular cells) (a) (inverted microscope × 1000), whereas the rosette formation was inhibited by pretreating the adherent cells with chromatography-purified human IgG-Fc (Fc␥) fragment (not shown). The rosette-forming small, round cells and large, irregular cells were confirmed to be FITC green-stained light chain-positive (tumor cells) and PE red-stained CD14-positive (monocytes/macrophages), respectively (b) (confocal microscope × 2000). Furthermore, the phagocytic study with the patient's serum. rhIFN␥ and M-CSF showed that monocytes/ macrophages (CD14-positive green cells) phagocytosed and then destroyed the tumor cells (PHK-26-stained red cells) in 3 and 6 h (c, d) (confocal microscope × 2000). rhlFN␥, human recombinant interferon ␥; M-CSF, macrophage colony-stimulating factor; PHK-26, dye for cell-membrane staining.
On the other hand, the () cells did not form rosettes with the adherent cells pretreated with the Fc␥ fragment ( cells).
Phagocytosis of tumor cells by monocytes/macrophages
After being co-cultured with the patient's serum, the rhIFN␥ and M-CSF-activated monocytes/macrophages (CD14-positive green cells) phagocytosed and destroyed the tumor cells (PKH-26-stained red cells) in 3 and 6 h, respectively (Figure  4c, d; confocal microscope) .
Reactivity of anti-tumor antibody
The cultured cells treated with the purified F (abЈ) 2 fragments and then double-stained with both anti-and light chain antibodies presented a dual-positive two-color profile which was the same as that of the cells treated with the serum.
In contrast, the patient's PHA-activated T cells, which were confirmed to coexpress CD3, HLA-A, B, C+ and HLA-DR+, presented neither ␥ heavy chain nor light chain on their surface even after incubation with the patient's serum. Furthermore, normal B cells including surface IgA-expressing cells derived from healthy volunteers did not demonstrate dual positivity even after addition of the patient's serum (datum not shown). Consequently, none of these non-tumor cells seemed to be coated with the patient's serum antibody.
To our regret, in the present study we could not investigate directly what kind of molecules on the tumor cell surface were the targets of the anti-tumor antibody because the volume of the tumor cells obtained from the patient's peripheral blood was too small to isolate the surface molecules including idiotype and there were no surface lymph node swellings.
Discussion
The monoclonal immunoglobulin idiotype expressed on the surface of neoplastic B cells is a well-known, representative tumor-specific antigen and therefore is considered a most suitable target of specific immunotherapy. Actually, idiotype-specific mouse monoclonal antibodies tailor-made by hybridoma techniques have been used to treat patients with B cell nonHodgkin's lymphoma (B-NHL) expressing the surface immunoglobulin, and partially successful outcomes have been noted in some cases. 11, 12 It has also recently been reported that active immunization with autologous tumorimmunoglobulin idiotype plus an adjuvant induced the production of anti-idiotype antibody in vivo in B-NHL patients and that tumors regressed completely in two cases. 13, 14 These results suggest that tumors can spontaneously regress if antibodies against the neoplastic idiotype are produced naturally in vivo. However, no lymphoma cell-associated antibodies, such as the natural anti-idiotype antibody, have yet been reported because the methodology for their detection has not been established.
On the other hand, if extrinsic or serum immunoglobulins were bound to the surface of neoplastic B cells, they should modify the intrinsic surface immunoglobulins, particularly the composition of and light chains, that is, the extrinsic immunoglobulin-coated B-NHL could take the form ofdual-positive lymphoma.
To date, we have confirmed the diagnosis of B cell tumors by using the modified methods 1-3 of single-color FCM analysis for surface immunoglobulin and light chains. Later, we unexpectedly encountered several lymphoma cases expressing both and light chains ( -dual-positive lymphoma). According to our data, the -dual-positive lymphoma comprised approximately 5% (5/97) of B cell lymphomas expressing surface immunoglobulin. All five cases genotypically showed the rearrangement of only one light-chain gene. One of these cases has already been reported. 4 Recently, we were fortunate to encounter a fifth case, namely, the present -dual-positive lymphoma. This case was also found to have a genotypically monoclonal nature because the tumor cells showed fewer than two rearranged JH gene bands. In addition, the C gene was rearranged, but the J gene was in the germline configuration. These findings implied that the light chain on the tumor-cell surface, at least, was derived from the outside, ie from serum, and therefore serum immunoglobulin bearing the light chain was extrinsically bound to the tumor cells. This conclusion was supported by the fact that the tumor cells lost surface IgG chain after 1 week of culture, but regained it after incubation with the patient's serum (Figure 3b, c) .
Secondly, to clarify how this serum-derived IgG was bound to the tumor cells, we examined the two-color profile of ␥ heavy chain and Fc␥RII (CD32) because the tumor cells expressed only Fc␥RII of the three Fc␥ receptors (Fc␥RI-III), and found that there was no correlation between the densities of these two surface molecules. On the other hand, the cultured -single-positive tumor cells, although pretreated with an excess amount of the Fc␥ fragment, acquired dual positivity again after the addition of the patient's serum. Furthermore, the cultured tumor cells treated with the F(abЈ) 2 fragments purified from the patient's serum IgG also showed dual positivity. These findings, and the results of the rosette formation study and its inhibition test by the Fc␥ fragment suggested that the patient's serum IgG combined with some antigens on the tumor-cell surface via its Fab portion and with the Fc␥R of monocytes or macrophages via its Fc portion.
The antigen to which IgG was bound remained unclear. However, it reacted with neither HLA-A, B, C, DR+ T cells taken from the patient nor normal B cells including surface IgA-expressing cells obtained from healthy volunteers. Namely, IgG may not have been produced against HLA antigens or pan-B cell antigens or the constant region of IgA. On the other hand, the two-color study showed a positive correlation between the surface densities of both and light chains on the tumor cells. This suggested the direct binding of serum IgG and intrinsic surface IgA. Additionally, IgA did not have the characteristics of an anti-pan-IgG antibody such as the rheumatoid factor, because the IgA-expressing tumor cells obtained by 1-week culture showed no dual positivity even after treatment with heat-aggregated human IgG. Therefore, it may be reasonable to consider that the IgGtype serum anti-idiotype antibody became bound to the idiotype of monoclonal IgA expressed on the tumor cells. However, in the present study, we could not verify whether the patient's serum IgG had anti-idiotypic activity because the sample volume was too small to isolate the idiotype from the tumor cells. In the future, if the patient relapses with superficial lymphadenopathies, we plan to remove the mass and prove the anti-idiotypic activity of the patient's serum by an ELISA assay.
On the other hand, if IgG actually behaved in vivo as it did in vitro, the spontaneous reduction of leukemic lymphoma cells in the present case could be explained by mechanisms Leukemia such as phagocytosis or antibody-dependent cytotoxicity by monocytes or macrophages, which seems to be supported by a recent report 10 showing artificially made bispecific antibody-mediated macrophage phagocytosis of lymphoma cells through the Fc␥ receptor.
Finally, it was speculated that the present anti-tumor antibodies included not only IgG, but also IgG, because they should have a reactive nature and therefore should be produced polyclonally. However, we could not distinguish the light chain of the serum-derived IgG from that of the tumorcell-expressing IgA because of the technical difficulties.
In conclusion, the -dual-positive lymphomas might have been overlooked until now because of artificial errors. In the future, when a case is diagnosed immunohistochemically as having a B-NHL, its phenotype should be confirmed by twocolor FCM analysis. If the case were -dual-positive, it could be regarded as an anti-tumor antibody-coated B cell lymphoma, because the lymphoma derived from a -hybrid B cell clone [15] [16] has not been reported until now. The existence of the anti-tumor antibody-coated lymphoma may suggest the possibility that the immune system actually produces antibodies in vivo against some tumor surface antigens such as idiotype, and furthermore, the anti-tumor antibody-mediated immunological mechanism causes the spontaneous regression unusually seen in some lymphomas such as our case.
